Construction of a Live-Attenuated Vaccine Strain of Yersinia pestis EV76-B-SHUΔpla and Evaluation of Its Protection Efficacy in a Mouse Model by Aerosolized Intratracheal Inoculation

Junxia Feng,Yingying Deng,Mengjiao Fu,Xueyuan Hu,Wenbo Luo,Zhiyu Lu,Lupeng Dai,Huiying Yang,Xiaodong Zhao,Zongmin Du,Bohai Wen,Lingxiao Jiang,Dongsheng Zhou,Jun Jiao,Xiaolu Xiong
DOI: https://doi.org/10.3389/fcimb.2020.00473
IF: 6.073
2020-09-08
Frontiers in Cellular and Infection Microbiology
Abstract:Plague, which is caused by <i>Yersinia pestis</i>, is one of the most dangerous infectious diseases. No FDA-approved vaccine against plague is available for human use at present. To improve the immune safety of <i>Y. pestis</i> EV76 based live attenuated vaccine and to explore the feasibility of aerosolized intratracheal inoculation (i.t.) route for vaccine delivery, a plasminogen activator protease (<i>pla</i>) gene deletion mutant of the attenuated <i>Y. pestis</i> strain EV76-B-SHU was constructed, and its residual virulence and protective efficacy were evaluated in a mouse model via aerosolized intratracheal inoculation (i.t.) or via subcutaneous injection (s.c.). The residual virulence of EV76-B-SHUΔ<i>pla</i> was significantly reduced compared to that of the parental strain EV76-B-SHU following i.t. and s.c. infection. The EV76-B-SHUΔ<i>pla</i> induced higher levels of mucosal antibody sIgA in the bronchoalveolar lavage fluid of mice immunized by i.t. but not by s.c.. Moreover, after lethal challenge with <i>Y. pestis</i> biovar Microtus strain 201 (avirulent in humans), the protective efficacy and bacterial clearance ability of the EV76-B-SHUΔ<i>pla</i>-i.t. group were comparable to those of the EV76-B-SHUΔ<i>pla</i>-s.c. and EV76-B-SHU immunized groups. Thus, the EV76-B-SHUΔ<i>pla</i> represents an excellent live-attenuated vaccine candidate against pneumonic plague and aerosolized i.t. represents a promising immunization route in mouse model.
immunology,microbiology
What problem does this paper attempt to address?